Optimized Bacterial Vectors for Enzyme-Based mRNA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing clinical-grade enzymes for mRNA synthesis in therapeutic applications are inefficient and costly, lacking optimized plasmid constructs, protein production conditions, and purification protocols.
Innovation Solution
Optimized bacterial expression vectors with arabinose promoters and codon-optimized gene sequences for T7 RNA polymerase, Vaccinia Virus Capping Enzyme (VVCE) subunits, and Poly(A) polymerase, along with modified protein purification methods, including His tags and Tobacco Etch Virus protease sequences, are used to produce enzymes in-house, which are then applied in a sequential IVT process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If commercially available enzymes are used for mRNA synthesis, then the production process is simple, but the cost is high and the efficiency is low
Solution Approach 1:
The patent divides the mRNA production system into modular components: optimized plasmid constructs for enzyme production, purified recombinant enzymes (T7 RNA polymerase, Vaccinia virus capping enzyme, Poly(A) polymerase), and standardized IVT reaction conditions. This segmentation allows each component to be independently optimized while maintaining overall process simplicity.
Solution Approach 2:
The patent optimizes multiple parameters including plasmid construct design (promoter sequences, gene orientations), protein expression conditions (temperature, induction timing), purification parameters (chromatography conditions), and IVT reaction conditions (enzyme concentrations, incubation temperatures). These parameter optimizations collectively enhance mRNA production efficiency while maintaining process simplicity.
2Ease of operation
If commercially available enzymes are used for mRNA synthesis, then the process setup is straightforward, but the cost of enzymes is high
Solution Approach 1:
The patent enables laboratories to produce their own required enzymes through optimized plasmid constructs and standardized protocols. By providing self-contained plasmids that express T7 RNA polymerase, Vaccinia virus capping enzyme, and Poly(A) polymerase under optimized conditions, the system allows institutions to manufacture their own enzymes, eliminating dependence on expensive commercial purchases while maintaining ease of operation through standardized procedures.
3Ease of manufacture
If standard protein purification methods are used, then the purification process is simple, but the yield and quality of enzymes are insufficient
Solution Approach 1:
The patent incorporates preliminary optimization steps including designed plasmid constructs with optimized promoter sequences and gene orientations, pre-optimized expression conditions, and pre-characterized purification protocols. These preliminary actions ensure high-quality enzyme production before the actual purification process begins, achieving both simplicity and high manufacturing precision.
4Device complexity
If non-optimized plasmid constructs are used for enzyme production, then the cloning process is simple, but the protein expression yield is low
Solution Approach 1:
The patent applies local quality optimization to specific regions of the plasmid constructs, including optimized promoter sequences for high-level expression, strategically placed ribosome binding sites, and optimized gene orientations. These localized optimizations in critical regions achieve high protein expression yields without requiring complete redesign of entire plasmid systems, balancing simplicity and productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the yield and quality of mRNA production, as evidenced by improved protein expression and transfection efficiency in transfected cells, surpassing commercially available enzymes.
Implementation Method 1
The insert further comprises an arabinose promoter sequence upstream of the polymerase sequence
Implementation Method 2
addition of a Tobacco Etch Virus protease sequence, whereby the His tag sequence can be proteolytically removed subsequent to protein purification
Implementation Method 3
addition of nucleic acid sequences encoding His tags, wherein polymeric histidine is encoded in-frame with the protein sequence and placed at either the N or C terminus, and whereby proteins can be column purified after fermentation
Implementation Method 4
the purified T7 RNA Polymerase is added to a reaction comprising linearized plasmid DNA encoding an mRNA transcript of interest. RNA is thereby transcribed from the linearized DNA via the action of the T7 RNA Polymerase
Implementation Method 5
A second reaction comprises the RNA transcript from the first reaction, S-adenosyl Methionine, and purified VVCE. The RNA transcript is thereby capped at the N-terminal to generate cap 0 mRNA
Implementation Method 6
A third reaction comprises capped mRNA from the VVCE reaction, purified poly(A) polymerase, and ATP, whereby a poly-adenylated tail is added to the 3′ end of the capped mRNA transcript
Data Source
AI summary
A method for the production of proteins used in the in vitro transcription (IVT) of messenger RNA (mRNA), wherein the proteins are evaluated for purity and efficacy by the efficiency with which mRNA synthetically derived therefrom, subsequently transfects cells and produces encoded proteins.